Please assess the completion status of the following clinical trial:

Trial Title: Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent must be obtained before any assessment is performed~* Clinical diagnosis of chronic plaque-type psoriasis at least 6 months prior to randomization~* Moderate to severe plaque psoriasis as defined at baseline by:~  * ≥10% Body Surface Area (BSA) involvement and~ * PASI total score of ≥12 and~ * IGA mod 2011 score of ≥3 (based on a scale of 0-4)~Exclusion Criteria:~* Forms of diagnosed psoriasis other than chronic plaque psoriasis~* Medication-induced or medication exacerbated psoriasis~* Previous exposure to secukinumab or any other biologic drug directly targeting IL-17A or IL-17RA receptors~* Ongoing use of prohibited treatments~* Pregnant or nursing (lactating) women~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): Eligible patients received secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3 and 4 followed by monthly dosing up to Week 48
- Placebo (Type: PLACEBO_COMPARATOR): Eligible patients received placebo at randomization, Weeks 1, 2, 3, 4, and 8. At Week 12, patients were switched to treatment with secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48

Based on this trial design, predict the completion outcome and termination type (if applicable).